Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease
- PMID: 33454343
- DOI: 10.1016/j.amjcard.2021.01.005
Closing Gaps in Lifestyle Adherence for Secondary Prevention of Coronary Heart Disease
Abstract
The secondary prevention (SP) of coronary heart disease (CHD) has become a major public health and economic burden worldwide. In the United States, the prevalence of CHD has risen to 18 million, the incidence of recurrent myocardial infarctions (MI) remains high, and related healthcare costs are projected to double by 2035. In the last decade, practice guidelines and performance measures for the SP of CHD have increasingly emphasized evidence-based lifestyle (LS) interventions, including healthy dietary patterns, regular exercise, smoking cessation, weight management, depression screening, and enrollment in cardiac rehabilitation. However, data show large gaps in adherence to healthy LS behaviors and low rates of enrollment in cardiac rehabilitation in patients with established CHD. These gaps may be related, since behavior change interventions have not been well integrated into traditional ambulatory care models in the United States. The chronic care model, an evidence-based practice framework that incorporates clinical decision support, self-management support, team-care delivery and other strategies for delivering chronic care is well suited for both chronic CHD management and prevention interventions, including those related to behavior change. This article reviews the evidence base for LS interventions for the SP of CHD, discusses current gaps in adherence, and presents strategies for closing these gaps via evidence-based and emerging interventions that are conceptually aligned with the elements of the chronic care model.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest Todd M.Brown receives research support from Amgen, Inc. and serves as site PI for a clinical trial funded by Omthera Pharmaceuticals/Astra Zeneca. Robert Ostfeld has performed consulting work for Better Therapeutics LLC. Neil Gordon is the managing member of a commercial population health management company, INTERVENT International, LLC. Dean Ornish receives royalties from general-interest books on health; sometimes receives lecture honoraria; consulting and licensing fees from Sharecare; stock for being on the advisory board of Obvious Ventures, Andrew M. Freeman does nonpromotional speaking for Boehringer-Ingleheim, all remaining authors have no relevant disclosures.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
